Sharecare (SHCR)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.38 +0.01 (0.73%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SHCR 1.37 0.00(0.00%)
Will SHCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SHCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SHCR
Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Sharecare, Inc. (SHCR) to Report a Decline in Earnings: What to Look Out for
SHCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sharecare, Inc. (SHCR) Reports Q4 Loss, Lags Revenue Estimates
GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates
Life Time Group Holdings, Inc. (LTH) Q4 Earnings and Revenues Top Estimates
Other News for SHCR
SHCR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Sharecare to Boston Scientific
Key Takeaways From Sharecare Analyst Ratings
Sharecare price target raised by 43c at Morgan Stanley, here's why
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)
Hold Rating on Sharecare Amid Private Acquisition and Market Challenges